NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Price Target & More

$6.01 -0.03 (-0.50 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$6.04
Today's Range$5.74 - $6.08
52-Week Range$3.61 - $12.22
Volume13,981 shs
Average Volume74,769 shs
Market Capitalization$95.39 million
P/E Ratio-6.13
Dividend YieldN/A
Beta2.72

About Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals logoGalmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceuticals Ltd. is a subsidiary of Galmed International Ltd.

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448

Debt

Debt-to-Equity RatioN/A
Current Ratio4.99%
Quick Ratio4.99%

Price-To-Earnings

Trailing P/E Ratio-6.13
Forward P/E Ratio-7.81
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.09 million
Price / Sales85.13
Cash FlowN/A
Price / CashN/A
Book Value$1.24 per share
Price / Book4.85

Profitability

EPS (Most Recent Fiscal Year)($0.98)
Net Income$-12,290,000.00
Net Margins-1,133.55%
Return on Equity-133.50%
Return on Assets-94.64%

Miscellaneous

Employees16
Outstanding Shares15,440,000

How to Become a New Pot Stock Millionaire

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals (NASDAQ:GLMD) posted its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04. The biopharmaceutical company earned $0.27 million during the quarter, compared to analysts' expectations of $0.28 million. Galmed Pharmaceuticals had a negative net margin of 1,133.55% and a negative return on equity of 133.50%. View Galmed Pharmaceuticals' Earnings History.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Galmed Pharmaceuticals.

What price target have analysts set for GLMD?

4 brokerages have issued 1 year target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $14.00 to $32.00. On average, they anticipate Galmed Pharmaceuticals' stock price to reach $22.25 in the next year. View Analyst Ratings for Galmed Pharmaceuticals.

What are Wall Street analysts saying about Galmed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (1/11/2018)
  • 2. Maxim Group analysts commented, "Galmed reported 3Q17, spending just $2.8M and closing the period with $9M in cash. Management was clear that with their efforts to preserve cash, they have runway through 2018 and through catalysts; data from both ARRIVE and ARREST studies." (11/9/2017)

Who are some of Galmed Pharmaceuticals' key competitors?

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:
  • Mr. Allen Baharaff, Chief Exec. Officer, Pres and Director (Age 53)
  • Mr. Yohai Stenzler CPA, Chief Financial Officer and Controller (Age 35)
  • Mr. Guy Nehemya, VP of Operations (Age 33)
  • Dr. Liat Hayardeny Ph.D., MBA, Chief Scientific Officer (Age 51)
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 35)

Has Galmed Pharmaceuticals been receiving favorable news coverage?

Media stories about GLMD stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.05 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $6.01.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $95.39 million and generates $1.09 million in revenue each year. The biopharmaceutical company earns $-12,290,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Galmed Pharmaceuticals employs 16 workers across the globe.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 ZE`EV TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.


MarketBeat Community Rating for Galmed Pharmaceuticals (GLMD)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galmed Pharmaceuticals (NASDAQ:GLMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Galmed Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.25, suggesting that the stock has a possible upside of 270.22%. The high price target for GLMD is $32.00 and the low price target for GLMD is $14.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.25$22.25$20.75$17.00
Price Target Upside: 270.22% upside259.45% upside105.85% upside84.78% upside

Galmed Pharmaceuticals (NASDAQ:GLMD) Consensus Price Target History

Price Target History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ:GLMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2018Maxim GroupSet Price TargetBuy$14.00HighView Rating Details
2/12/2018HC WainwrightBoost Price TargetBuy -> Buy$18.00 -> $24.00LowView Rating Details
11/15/2017Roth CapitalInitiated CoverageBuy -> Buy$32.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$19.00N/AView Rating Details
8/5/2016FBR & CoSet Price TargetBuy$20.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Galmed Pharmaceuticals (NASDAQ:GLMD) Earnings History and Estimates Chart

Earnings by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ:GLMD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.16)($0.16)($0.16)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181($0.04)($0.04)($0.04)

Galmed Pharmaceuticals (NASDAQ GLMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018($0.20)N/AView Earnings Details
3/13/2018Not Specified($0.23)($0.27)$0.28 million$0.27 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.27)($0.23)$0.26 million$0.27 millionViewN/AView Earnings Details
7/31/20176/30/2017($0.33)($0.22)$0.29 million$0.27 millionViewN/AView Earnings Details
5/15/20173/31/2017($0.39)($0.26)$0.29 million$0.27 millionViewN/AView Earnings Details
3/23/201712/31/2016($0.30)($0.40)$0.22 million$0.27 millionViewN/AView Earnings Details
11/7/2016Q3($0.39)($0.34)$0.19 millionViewListenView Earnings Details
8/3/2016Q216($0.35)($0.39)ViewN/AView Earnings Details
5/16/2016Q116($0.33)($0.36)ViewListenView Earnings Details
3/22/2016Q415($0.28)($0.29)ViewListenView Earnings Details
11/9/2015Q315($0.29)($0.23)ViewN/AView Earnings Details
8/13/2015Q215($0.28)($0.21)ViewListenView Earnings Details
5/13/2015Q1($0.26)($0.22)ViewListenView Earnings Details
3/31/2015($0.36)($0.15)ViewN/AView Earnings Details
7/25/2014Q2 2014($0.15)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Galmed Pharmaceuticals (NASDAQ:GLMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Galmed Pharmaceuticals (NASDAQ GLMD) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 17.69%
Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)
Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ GLMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Galmed Pharmaceuticals (NASDAQ GLMD) News Headlines

Source:
DateHeadline
What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years?What Are Analysts Expecting From Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Over The Next Few Years?
finance.yahoo.com - April 20 at 5:21 PM
Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASHGalmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASH
finance.yahoo.com - April 16 at 8:16 AM
Galmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Buy" from BrokeragesGalmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 14 at 3:31 AM
Zacks: Brokerages Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $290,000.00Zacks: Brokerages Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $290,000.00
www.americanbankingnews.com - April 13 at 1:00 AM
Galmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.21 Per ShareGalmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 11 at 11:16 PM
InMed Announces Appointment of Joshua Blacher as Chief Business OfficerInMed Announces Appointment of Joshua Blacher as Chief Business Officer
finance.yahoo.com - April 11 at 8:31 AM
Zacks Investment Research Downgrades Galmed Pharmaceuticals (GLMD) to HoldZacks Investment Research Downgrades Galmed Pharmaceuticals (GLMD) to Hold
www.americanbankingnews.com - April 7 at 3:22 PM
Galmed Pharmaceuticals (GLMD) Upgraded at ValuEngineGalmed Pharmaceuticals (GLMD) Upgraded at ValuEngine
www.americanbankingnews.com - April 4 at 12:02 AM
Galmed Pharmaceuticals (GLMD) Given a $14.00 Price Target at Maxim GroupGalmed Pharmaceuticals (GLMD) Given a $14.00 Price Target at Maxim Group
www.americanbankingnews.com - April 3 at 1:20 PM
Galmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct OfferingGalmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering
finance.yahoo.com - April 3 at 8:24 AM
Galmed Pharmaceuticals (GLMD) Rating Lowered to Strong Sell at ValuEngineGalmed Pharmaceuticals (GLMD) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 28 at 11:55 AM
Zacks: Brokerages Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Post Quarterly Sales of $290,000.00Zacks: Brokerages Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Post Quarterly Sales of $290,000.00
www.americanbankingnews.com - March 28 at 10:53 AM
Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on ...Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on ...
www.prnewswire.com - March 27 at 5:14 PM
Galmed Pharmaceuticals (GLMD) PT Set at $14.00 by Maxim GroupGalmed Pharmaceuticals (GLMD) PT Set at $14.00 by Maxim Group
www.americanbankingnews.com - March 27 at 11:30 AM
Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASLGalmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
finance.yahoo.com - March 27 at 8:27 AM
Galmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from BrokeragesGalmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 20 at 3:34 AM
Galmed Pharmaceuticals Ltd to Post Q1 2018 Earnings of ($0.19) Per Share, SunTrust Banks Forecasts (GLMD)Galmed Pharmaceuticals Ltd to Post Q1 2018 Earnings of ($0.19) Per Share, SunTrust Banks Forecasts (GLMD)
www.americanbankingnews.com - March 16 at 8:18 AM
Galmed Pharmaceuticals (GLMD) Upgraded to "Sell" by ValuEngineGalmed Pharmaceuticals (GLMD) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM
Aramchols Failed Past Isnt Its Future; Galmed Gets An UpgradeAramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade
finance.yahoo.com - March 15 at 6:12 PM
Galmed Pharmaceuticals (GLMD) Raised to "Buy" at Maxim GroupGalmed Pharmaceuticals (GLMD) Raised to "Buy" at Maxim Group
www.americanbankingnews.com - March 15 at 8:08 AM
Galmed Pharmaceuticals (GLMD) to Release Earnings on WednesdayGalmed Pharmaceuticals (GLMD) to Release Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:16 AM
Galmed Pharmaceuticals (GLMD) Releases  Earnings Results, Misses Estimates By $0.04 EPSGalmed Pharmaceuticals (GLMD) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 13 at 10:56 AM
Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateGalmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 8:25 AM
Galmed Pharmaceuticals (GLMD) to Release Earnings on TuesdayGalmed Pharmaceuticals (GLMD) to Release Earnings on Tuesday
www.americanbankingnews.com - March 6 at 9:19 AM
Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13
finance.yahoo.com - March 5 at 8:17 AM
Galmed Pharmaceuticals to Participate in Investor Conferences in MarchGalmed Pharmaceuticals to Participate in Investor Conferences in March
finance.yahoo.com - March 2 at 8:16 AM
Galmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Path To ProfitabilityGalmed Pharmaceuticals Ltd’s (NASDAQ:GLMD) Path To Profitability
finance.yahoo.com - March 1 at 8:15 AM
Galmed Pharmaceuticals (GLMD) Downgraded by ValuEngineGalmed Pharmaceuticals (GLMD) Downgraded by ValuEngine
www.americanbankingnews.com - February 28 at 10:16 PM
Galmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Hold" from AnalystsGalmed Pharmaceuticals Ltd (GLMD) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 23 at 3:30 AM
Zacks: Analysts Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00Zacks: Analysts Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - February 22 at 3:06 PM
Galmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.23 Per ShareGalmed Pharmaceuticals Ltd (GLMD) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 20 at 1:22 AM
Galmed Pharmaceuticals Ltd (GLMD) Forecasted to Post FY2022 Earnings of $0.03 Per ShareGalmed Pharmaceuticals Ltd (GLMD) Forecasted to Post FY2022 Earnings of $0.03 Per Share
www.americanbankingnews.com - February 19 at 9:18 AM
ValuEngine Lowers Galmed Pharmaceuticals (GLMD) to SellValuEngine Lowers Galmed Pharmaceuticals (GLMD) to Sell
www.americanbankingnews.com - February 14 at 11:42 PM
Galmed Pharmaceuticals (GLMD) Cut to "Hold" at Maxim GroupGalmed Pharmaceuticals (GLMD) Cut to "Hold" at Maxim Group
www.americanbankingnews.com - February 14 at 12:32 PM
Galmed Pharmas stock loses more than half its value after drug trial misses endpointGalmed Pharma's stock loses more than half its value after drug trial misses endpoint
finance.yahoo.com - February 14 at 9:51 AM
Galmed Announces ARRIVE Study DataGalmed Announces ARRIVE Study Data
finance.yahoo.com - February 14 at 9:51 AM
HC Wainwright Raises Galmed Pharmaceuticals (GLMD) Price Target to $24.00HC Wainwright Raises Galmed Pharmaceuticals (GLMD) Price Target to $24.00
www.americanbankingnews.com - February 12 at 11:46 AM
Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare ConferenceGalmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:11 AM
Galmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial BenefitsGalmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits
finance.yahoo.com - February 7 at 9:35 AM
Zacks: Analysts Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00Zacks: Analysts Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00
www.americanbankingnews.com - February 5 at 6:58 AM
-$0.23 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter-$0.23 Earnings Per Share Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter
www.americanbankingnews.com - February 3 at 3:14 AM
Galmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from AnalystsGalmed Pharmaceuticals Ltd (GLMD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 29 at 3:30 AM
The Race To Find A Treatment For NASH - Nasdaq.com - NasdaqThe Race To Find A Treatment For NASH - Nasdaq.com - Nasdaq
www.nasdaq.com - January 16 at 9:58 AM
Galmed Pharmaceuticals (GLMD) Lowered to Hold at Zacks Investment ResearchGalmed Pharmaceuticals (GLMD) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 11 at 11:54 PM
Zacks Investment Research Upgrades Galmed Pharmaceuticals (GLMD) to "Buy"Zacks Investment Research Upgrades Galmed Pharmaceuticals (GLMD) to "Buy"
www.americanbankingnews.com - January 11 at 12:10 AM
Galmed Pharmaceuticals Ltd (GLMD) Given Average Recommendation of "Buy" by BrokeragesGalmed Pharmaceuticals Ltd (GLMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 4 at 4:02 AM
Maxim Group Analysts Give Galmed Pharmaceuticals (GLMD) a $14.00 Price TargetMaxim Group Analysts Give Galmed Pharmaceuticals (GLMD) a $14.00 Price Target
www.americanbankingnews.com - January 3 at 8:00 PM
Galmed Pharma (GLMD) Reports Gross Proceeds of $11.6 Million Under ATM Programs During December 2017Galmed Pharma (GLMD) Reports Gross Proceeds of $11.6 Million Under ATM Programs During December 2017
www.streetinsider.com - January 3 at 9:17 AM
$280,000.00 in Sales Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter$280,000.00 in Sales Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter
www.americanbankingnews.com - January 2 at 4:12 PM
Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017
finance.yahoo.com - January 2 at 9:52 AM

SEC Filings

Galmed Pharmaceuticals (NASDAQ:GLMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galmed Pharmaceuticals (NASDAQ:GLMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galmed Pharmaceuticals (NASDAQ GLMD) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.